Volume 89, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Treatment alternatives have seldom been evaluated in children with cutaneous leishmaniasis (CL). We examine the clinical/epidemiological profile of children with CL considering international guidelines for local treatment. Descriptive analyses were conducted using International Center for Medical Research and Training (CIDEIM) case reports of parasitologically diagnosed patients ≤ 14 years of age from 2004 to 2010. Eligibility for local treatment based on World Health Organization/Pan American Health Organization (WHO/PAHO) criteria was determined. Among 380 children, 90% presented lesions of < 3 months duration, 54% presented single lesions < 30 mm in diameter, and 45% were ≤ 5 years old. Lesions on the head and neck were more frequent among children 0–5 years, and lesions below the head/neck were more frequent among 11- to 14-year-old children ( = 0.004). Using PAHO and WHO criteria, 26% and 53% of children, respectively, were eligible for local treatment. Recommended local treatments for New World CL have potential but limited applicability in children. Individual risk–benefit assessment and effectiveness data in children may increase eligibility.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Palacios R, Osorio LE, Grajales LF, Ochoa MT, , 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am J Trop Med Hyg 64: 187193. [Google Scholar]
  2. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo Saravia NG, , 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 195: 602608.[Crossref] [Google Scholar]
  3. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Pérez M, Nicholls RS, Gore Saravia N, , 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205: 684692.[Crossref] [Google Scholar]
  4. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, , 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.[Crossref] [Google Scholar]
  5. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S, , 2011. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255260.[Crossref] [Google Scholar]
  6. Bonfante-Garrido R, Melendez E, Barroeta S, de Alejos MA, Momen H, Cupolillo E, , 1992. Cutaneous leishmaniasis in western Venezuela caused by infection with Leishmania venezuelensis and L. braziliensis variants. Trans R Soc Trop Med Hyg 86: 141148.[Crossref] [Google Scholar]
  7. Bittencourt AL, Barral A, Costa JM, , 1996. Tegumentary leishmaniasis in chilhood. Pediatr Dermatol 13: 455463.[Crossref] [Google Scholar]
  8. Desjeux P, , 1991. Information on the Epidemiology and Control of the Leishmaniasis by Country or Territory. Geneva: World Health Organization. [Google Scholar]
  9. García A, Parrado L, Rojas R, Delgado E, Dujardin R, Reithinger R, , 2009. Leishmaniasis in Bolivia: comprehensive review and current status. Am J Trop Med Hyg 80: 704711. [Google Scholar]
  10. Oliveira CC, Lacerda HG, Martins DR, Barbosa JD, Monteiro GR, Queiroz JW, Sousa JM, Ximenes MF, Jeronimo SM, , 2004. Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban-rural interface. Acta Trop 90: 155162.[Crossref] [Google Scholar]
  11. Montoya J, Jaramillo C, Palma G, Gomez T, Segura I, Travi B, , 1990. Report of an epidemic outbreak of tegumentary leishmaniasis in a coffee-growing area of Colombia. Mem Inst Oswaldo Cruz 85: 119121.[Crossref] [Google Scholar]
  12. World Health Organization, 2002. Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol Rec 77: 365372. [Google Scholar]
  13. World Health Organization, 2010. Control of the Leishmaniasis: Report of the Meeting of the WHO Expert Committee on the Control of Leishmaniasis. Technical Reports Series 949. Geneva: World Health Organization. [Google Scholar]
  14. Weigle K, de Dávalos M, Heredia P, Molineros R, Saravia N, D'Alessandro A, , 1987. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: comparison of seven methods. Am J Trop Med Hyg 36: 489496. [Google Scholar]
  15. McMahon-Pratt D, David JR, , 1981. Monoclonal antibodies that distinguish between New World species of Leishmania . Nature 291: 581582.[Crossref] [Google Scholar]
  16. Saravia N, Segura I, Holguin A, Santrich C, Valderrama C, Ocampo C, , 1988. Epidemiologic, genetic and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg 59: 8694. [Google Scholar]
  17. Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG, , 1993. Epidemiology of cutaneous leishmaniasis in Colombia: environmental and behavioral risk factors for infection, clinical manifestations, and pathogenicity. J Infect Dis 168: 709714.[Crossref] [Google Scholar]
  18. Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi G, Jr Fernandes O, , 1998. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 178: 911914.[Crossref] [Google Scholar]
  19. Vergel C, Palacios R, Cadena H, Posso C, Valderrama L, Perez M, Walker J, Travi BLT, Saravia NG, , 2006. Evidence for Leishmania Viannia in skin and blood of patients before and after treatment. J Infect Dis 194: 503511.[Crossref] [Google Scholar]
  20. Figueroa RA, Lozano LE, Romero IC, Cardona MT, Prager M, Diaz YR, Tellez JA, Saravia NG, , 2009. Detection of Leishmania in unaffected mucosal tissues of patients with American cutaneous leishmaniasis. J Infect Dis 200: 638646.[Crossref] [Google Scholar]
  21. Romero IC, Tellez J, Suárez Y, Cardona MT, Figueroa R, Zelazny A, Saravia NG, , 2010. Viability and burden of Leishmania in extralesional sites during human dermal leishmaniasis. PLoS Negl Trop Dis 4: e819.[Crossref] [Google Scholar]
  22. de Oliveira Camera P, Junger J, do Espírito Santo Silva Pires F, Mattos M, Oliveira-Neto MP, Fernandes O, Pirmez C, , 2006. Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 100: 11121117.[Crossref] [Google Scholar]
  23. Ampuero J, Macêdo V, Marsden P, , 2006. Clinical findings of tegumentary leishmaniasis in children under five years of age in an endemic area of Leishmania (Viannia) braziliensis . Rev Soc Bras Med Trop 39: 2226.[Crossref] [Google Scholar]
  24. Costa JM, Balby IT, Rocha EJ, da Silva AR, Rebêlo JM, Ferreira LA, Gama ME, Branco M dos R, Burattini MN, Soares N de J, , 1998. Comparative study of American tegumentary leishmaniasis between childhood and teenagers from the endemic areas Buriticupu, Maranhao and Corte de Pedra, Bahia, Brazil. Rev Soc Bras Med Trop 31: 279288.[Crossref] [Google Scholar]
  25. Pinto MC, Campbell-Lendrum DH, Lozovei AL, Teodoro U, Davies CR, , 2001. Phlebotomine sandfly responses to carbon dioxide and human odour in the field. Med Vet Entomol 15: 132139.[Crossref] [Google Scholar]
  26. Navin TR, Arana BA, Arana FE, de Mérida AM, Castillo AL, Pozuelos JL, , 1990. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 42: 4350. [Google Scholar]
  27. Lobo IM, Soares MB, Correia TM, de Freitas LA, Oliveira MI, Nakatani M, Netto E, Badaro R, David JR, , 2006. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg 100: 642649.[Crossref] [Google Scholar]
  28. López L, Robayo M, Vargas M, Vélez ID, , 2012. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 17: 1358. [Google Scholar]
  29. Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, Kolaczinski J, David JR, . 2005. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40: 11481155.[Crossref] [Google Scholar]
  30. Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, Polhemus ME, Yoon IK, Hummer KA, Gasser RA, Jr Oster CN, Benson PM, . 2010. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 4: e628.[Crossref] [Google Scholar]
  31. Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, Cruz M, Gracia L, Villarroel D, Alavi I, Toledo J, Berman J, , 2013. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 12551260.[Crossref] [Google Scholar]
  32. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M, , 2009. WR279, 396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3: e432.[Crossref] [Google Scholar]
  33. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M, . 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524532.[Crossref] [Google Scholar]
  34. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, , 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 15: CD004834. [Google Scholar]

Data & Media loading...


  • Received : 30 Dec 2012
  • Accepted : 20 May 2013
  • Published online : 07 Aug 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error